Differential endopeptidase activity of different forms of type A botulinum neurotoxin: A unique relationship between the size of the substrate and activity of the enzyme

Toxicon ◽  
2018 ◽  
Vol 144 ◽  
pp. 34-41 ◽  
Author(s):  
Ghuncha Ambrin ◽  
Raj Kumar ◽  
Bal Ram Singh
PLoS ONE ◽  
2014 ◽  
Vol 9 (10) ◽  
pp. e111238 ◽  
Author(s):  
Jacob M. Scherf ◽  
Xiaoyang Serene Hu ◽  
William H. Tepp ◽  
Konstantin Ichtchenko ◽  
Eric A. Johnson ◽  
...  

2014 ◽  
Vol 57 ◽  
pp. 207-212 ◽  
Author(s):  
Christian Lévêque ◽  
Géraldine Ferracci ◽  
Yves Maulet ◽  
Christelle Mazuet ◽  
Michel Popoff ◽  
...  

2002 ◽  
Vol 115 (3) ◽  
pp. 667-673 ◽  
Author(s):  
Gary W. Lawrence ◽  
J. Oliver Dolly

The changes that SNAREs undergo during exocytosis were studied in permeabilised chromaffin cells treated with Ca2+, MgATP or botulinum neurotoxin A. High-resolution 2D SDS-PAGE revealed multiple SDS-resistant SNARE complexes having a wide range of sizes and in which SNAP-25 and syntaxin predominate over synaptobrevin. Their formation increased upon Ca2+-stimulated exocytosis; notably, the 2D protocol proved much superior to 1D SDS-PAGE for the detection of large complexes and revealed that for forms with relative molecular mass greater than 100,000 stimulated induction was more significant than for smaller species. MgATP enhanced Ca2+-triggered catecholamine release but reduced the content of complexes. By contrast, botulinum neurotoxin type A inhibited exocytosis and altered the stoichiometry of the SNAP-25:syntaxin binary association, without lowering its abundance. The individual SNAREs were protected against trypsin proteolysis to varying extents in binary and ternary complexes of different sizes, suggestive of distinct folding intermediates. Our data suggest that Ca2+ triggers an early stage of SNARE complex formation causing an accumulation of partially folded intermediates, especially of binary forms, as well as their maturation into smaller, more protease resistant states. In addition, botulinum neurotoxin A inhibits exocytosis by perturbing the syntaxin:SNAP-25 ratio in binary intermediates.


2010 ◽  
Vol 40 (1) ◽  
pp. 29 ◽  
Author(s):  
Yun Jeong Kim ◽  
Joung Hee Baek ◽  
Jeong-Hee Kim ◽  
Bong Su Kim ◽  
Gi-eun Rhie ◽  
...  

Planta Medica ◽  
2015 ◽  
Vol 81 (11) ◽  
Author(s):  
C Yalamanchili ◽  
VK Manda ◽  
AG Chittiboyina ◽  
WA Harrell Jr ◽  
RP Webb ◽  
...  

2017 ◽  
Vol 36 (05) ◽  
pp. 315-323
Author(s):  
N. Üçeyler ◽  
C. Sommer

ZusammenfassungDie Behandlung neuropathischer Schmerzen mit systemisch wirksamen oral verabreichten Pharmaka ist bei vielen Patienten wirksam, kann jedoch zu zentralnervösen unerwünschten Wirkungen wie Müdigkeit oder Schwindel führen. Daher sind in den letzten Jahren topische Therapien in das Zentrum der Aufmerksamkeit gerückt. Botulinumtoxin, etabliert in der Therapie von Dystonien und Spastik, wurde zunehmend bei Schmerzerkrankungen getestet, hierbei ist Botulinum-Neurotoxin A der am besten untersuchte Serotyp. Die häufigsten Indikationen waren Schmerzen im Trigeminusversorgungsbereich und periphere neuropathische Schmerzen. Bei den meisten Studien war Botulinum-Neurotoxin A Placebo deutlich überlegen. Präklinische Studien zum Wirkmechanismus erbrachten die Erkenntnis, dass neben dem erwarteten peripheren Effekt sehr wahrscheinlich auch eine zentrale Reduktion der Ausschüttung von exzitatorischen Neurotransmittern an der Wirkung beteiligt ist.


Sign in / Sign up

Export Citation Format

Share Document